Here are relevant reports on : OTC-drug
-
Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region – Global Forecast to 2028
Biosimilars market growth is primed to transition from 29.4 billion in 2023 to USD 66.9 billion by 2028, showcasing a strong CAGR of 17.8%. This market is driven by increasing demand for cost-effective treatments amidst rising chronic disease rates and the patent expirations of major biologics. Key trends include the rapid approval and adoption of biosimilars, particularly in oncology.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023
The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
- Published: May 2018
- Price: $ 4950
- TOC Available:
-
Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti–Epileptic Drugs,Anti–Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029
The global therapeutic drug monitoring market growth is primed to transition from USD 2.30 billion in 2024 to USD 3.44 billion by 2029, showcasing a strong CAGR of 8.4%. This growth is brought on by a number of causes, such as the rise in chronic diseases like cancer, heart disease, epilepsy, and autoimmune conditions.In addition, the development of advanced and highly sensitive immunoassay methods including fluorescence, chemiluminescence, and ELISA is also contributing considerably to the expansion of the TDM industry.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Drug Screening Market Size by Product (Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Urine, Breath, Hair), Drug (Alcohol, Cannabis, Opioids), End User (Workplace, Hospital, Law) - Global Forecast to 2029
The global drug screening market, valued at US$7.7B in 2023, is forecasted to grow at a 16.6% CAGR, reaching US$9.1B by 2024 and US$19.5B by 2029. Bans on alcohol consumption in Islamic countries may restrain the growth of this market to a certain extent.
- Published: May 2024
- Price: $ 4950
- TOC Available:
-
Life Science Analytics Market by Type (Descriptive, Prescriptive, Predictive), Service (Analytics), Application (Drug Discovery, Trials, RWE, Access, Sales & marketing, Drug Safety), End User (Pharma, Medical Device), & Region - Global Forecast to 2029
The global life science analytics market growth is primed to transition from $35.69 billion in 2024 to $61.94 billion by 2029, showcasing a strong CAGR of 11.7%. The growing focus on quality control, regulatory compliance, developed healthcare & life sciences infrastructure, and the surging demand for digitalized technologies across North America further propels the growth.
- Published: October 2024
- Price: $ 4950
- TOC Available:
-
Chemoinformatics Market by Application (Chemical Analysis (Chemical Databases, Chemo Metrics, Molecular Modelling), Drug Discovery (High Throughput Screening, Lead Identification and Optimization, QSAR/QSPR), Drug Validation) - Global Forecast to 2023
Growth of the chemoinformatics market is primarily driven by innovations and advancements in the drug development process, advances in the computer technology, increased demand of personalized medicine. On the other hand, cost associated with the chemoinformatics software is one of the major factors restraining the growth of this market. Whereas emerging markets are expected to provide significant growth opportunities in this market.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Glioblastoma Multiforme Drug Market by Therapy (Chemotherapy, Immunotherapy), Drug Class, End Use, Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast to 2027
The global glioblastoma multiforme drug market is projected to reach USD ~880 million by 2027 from USD 600 million in 2022, at a CAGR of 8% during the forecast period
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Drug Eluting Stents Market - 2019 By Types, Application & Geography
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Drug Discovery Outsourcing Market - 2019 By Types, Application & Geography
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Top 10 Drug Discovery Technologies Market – Strategic Analysis and Global Forecasts (2010 to 2015)
The top 10 drug discovery technologies play a vital role in the growth of the entire pharmaceutical industry as they are the key contributors in the swift introduction of blockbusters and innovative drugs, which is the most important aspect for the pharmaceutical companies.
- Published: November 2010
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
